BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Serfaty L, Aumaître H, Chazouillères O, Bonnand A, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis: Determinants of Outcome of Compensated Hepatitis C Virus-Related Cirrhosis. Hepatology 1998;27:1435-40. [DOI: 10.1002/hep.510270535] [Cited by in Crossref: 288] [Cited by in F6Publishing: 268] [Article Influence: 15.2] [Reference Citation Analysis]
Number Citing Articles
1 Harada N, Hiramatsu N, Oze T, Yamada R, Kurokawa M, Miyazaki M, Yakushijin T, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, Takehara T. Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines. J Gastroenterol 2013;48:535-43. [DOI: 10.1007/s00535-012-0657-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Hamada H, Yatsuhashi H, Yano K, Daikoku M, Arisawa K, Inoue O, Koga M, Nakata K, Eguchi K, Yano M. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer. 2002;95:331-339. [PMID: 12124834 DOI: 10.1002/cncr.10662] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
3 Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32:344-355. [PMID: 20497143 DOI: 10.1111/j.1365-2036.2010.04370.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 127] [Article Influence: 10.2] [Reference Citation Analysis]
4 Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology. 1999;29:1596-1601. [PMID: 10216148 DOI: 10.1002/hep.510290528] [Cited by in Crossref: 144] [Cited by in F6Publishing: 137] [Article Influence: 6.3] [Reference Citation Analysis]
5 Francesco A, Esterita A, Giovanni N, Davide T, Silvia G, Anna M, Francesca L, Marco M, Mariarosa T, Antonio C, Constance M, Davide F, Enrico R, Massimo D, Giuseppe M. Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: A prospective study on patients with HCV related cirrhosis. World J Gastroenterol 2004; 10(21): 3099-3102 [PMID: 15457551 DOI: 10.3748/wjg.v10.i21.3099] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
6 Hung TH, Liang CM, Hsu CN, Tai WC, Tsai KL, Ku MK, Wang JW, Tseng KL, Yuan LT, Nguang SH, Yang SC, Wu CK, Hsu PI, Wu DC, Chuah SK. Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan. PLoS One. 2017;12:e0181858. [PMID: 28742130 DOI: 10.1371/journal.pone.0181858] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
7 Berenguer M. Natural History of Clinically Compensated Hepatitis C Virus–Related Graft Cirrhosis After Liver Transplantation. Hepatology 2000;32:852-8. [DOI: 10.1053/jhep.2000.17924] [Cited by in Crossref: 444] [Cited by in F6Publishing: 380] [Article Influence: 20.2] [Reference Citation Analysis]
8 Phillips KD, Brewer R. Pathophysiology of Hepatitis C and HIV Coinfection. Journal of the Association of Nurses in AIDS care 2003;14:27S-51S. [DOI: 10.1177/1055329003254855] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
9 Lawson A, Hagan S, Rye K, Taguri N, Ratib S, Zaitoun AM, Neal KR, Ryder SD, Irving WL. The natural history of hepatitis C with severe hepatic fibrosis. J Hepatol. 2007;47:37-45. [PMID: 17400322 DOI: 10.1016/j.jhep.2007.02.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
10 Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Appl Health Econ Health Policy 2013;11:65-78. [PMID: 23355388 DOI: 10.1007/s40258-012-0007-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
11 Li H, McMahon BJ, McArdle S, Bruden D, Sullivan DG, Shelton D, Deubner H, Gretch DR. Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology 2008;375:580-91. [PMID: 18343477 DOI: 10.1016/j.virol.2008.02.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
12 Runge M, Krensel M, Westermann C, Bindl D, Nagels K, Augustin M, Nienhaus A. Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany. Int J Environ Res Public Health 2020;17:E440. [PMID: 31936470 DOI: 10.3390/ijerph17020440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52. [PMID: 16614742 DOI: 10.7150/ijms.3.47] [Cited by in Crossref: 454] [Cited by in F6Publishing: 431] [Article Influence: 28.4] [Reference Citation Analysis]
14 Ziol M, Nault J, Aout M, Barget N, Tepper M, Martin A, Trinchet J, Ganne–carrié N, Vicaut E, Beaugrand M, N'kontchou G. Intermediate Hepatobiliary Cells Predict an Increased Risk of Hepatocarcinogenesis in Patients With Hepatitis C Virus-Related Cirrhosis. Gastroenterology 2010;139:335-343.e2. [DOI: 10.1053/j.gastro.2010.04.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
15 Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol 2016; 8(1): 69-73 [PMID: 26783422 DOI: 10.4254/wjh.v8.i1.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
16 Buti M, Esteban R. Long-term outcome after interferon therapy in patients with chronic hepatitis C. Annals of Hepatology 2007;6:267-9. [DOI: 10.1016/s1665-2681(19)31909-x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
17 D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-231. [PMID: 16298014 DOI: 10.1016/j.jhep.2005.10.013] [Cited by in Crossref: 1547] [Cited by in F6Publishing: 1305] [Article Influence: 91.0] [Reference Citation Analysis]
18 Talwalkar JA. An evidence-based approach to studies in cirrhosis and portal hypertension: medical management of mild to moderate ascites. Clinical Gastroenterology and Hepatology 2003;1:474-9. [DOI: 10.1016/s1542-3565(03)00225-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 de Oliveira AC, El-Bacha I, Vianna MV, Parise ER. Utility and limitations of APRI and FIB4 to predict staging in a cohort of nonselected outpatients with hepatitis C. Ann Hepatol. 2016;15:326-332. [PMID: 27049486 DOI: 10.5604/16652681.1198801] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
20 Berenguer M, Wright TL. Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease. Clinics in Liver Disease 2003;7:631-50. [DOI: 10.1016/s1089-3261(03)00059-x] [Cited by in Crossref: 11] [Article Influence: 0.6] [Reference Citation Analysis]
21 Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011;54:396-405. [PMID: 21520194 DOI: 10.1002/hep.24370] [Cited by in Crossref: 111] [Cited by in F6Publishing: 109] [Article Influence: 10.1] [Reference Citation Analysis]
22 Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-S50. [PMID: 15508101 DOI: 10.1053/j.gastro.2004.09.014] [Cited by in Crossref: 1497] [Cited by in F6Publishing: 1384] [Article Influence: 83.2] [Reference Citation Analysis]
23 Krahn M, Wong JB, Heathcote J, Scully L, Seeff L. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making. 2004;24:20-29. [PMID: 15005951 DOI: 10.1177/0272989x03261568] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
24 Poynard T, Moussalli J, Ratziu V, Regimbeau C, Opolon P. EFFECT OF INTERFERON THERAPY ON THE NATURAL HISTORY OF HEPATITIS C VIRUS-RELATED CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. Clinics in Liver Disease 1999;3:869-81. [DOI: 10.1016/s1089-3261(05)70244-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
25 Anastasiou J, Alisa A, Virtue S, Portmann B, Murray-lyon I, Williams R. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. European Journal of Gastroenterology & Hepatology 2010;22:474-80. [DOI: 10.1097/meg.0b013e328332dd0a] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
26 Nakagomi R, Tateishi R, Masuzaki R, Soroida Y, Iwai T, Kondo M, Fujiwara N, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Kato N, Moriya K, Ikeda H, Koike K. Liver stiffness measurements in chronic hepatitis C: Treatment evaluation and risk assessment. J Gastroenterol Hepatol. 2019;34:921-928. [PMID: 30393960 DOI: 10.1111/jgh.14530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
27 Hoffmann P, Quasdorff M, González-carmona MÁ, Caselmann WH. Recent patents on experimental therapy for hepatitis C virus infection (1999 – 2002). Expert Opinion on Therapeutic Patents 2005;13:1707-23. [DOI: 10.1517/13543776.13.11.1707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
28 Bruno S, Savojardo D, Almasio PL, Mondelli MU. Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med 2011;3:21-8. [PMID: 24367218 DOI: 10.2147/HMER.S16991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
29 Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010;8:192-199. [PMID: 19879972 DOI: 10.1016/j.cgh.2009.10.026] [Cited by in Crossref: 147] [Cited by in F6Publishing: 140] [Article Influence: 11.3] [Reference Citation Analysis]
30 Omata M, Kanda T, Yu M, Yokosuka O, Lim S, Jafri W, Tateishi R, Hamid SS, Chuang W, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J, Mccaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35. [DOI: 10.1007/s12072-012-9342-y] [Cited by in Crossref: 114] [Cited by in F6Publishing: 128] [Article Influence: 11.4] [Reference Citation Analysis]
31 Kotha S, Neong S, Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev Mol Diagn 2018;18:713-22. [PMID: 30019978 DOI: 10.1080/14737159.2018.1496020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
32 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
33 Dantzler TE, Lawitz EJ. Treatment of chronic hepatitis C in nonresponders to previous therapy. Curr Gastroenterol Rep 2003;5:78-85. [DOI: 10.1007/s11894-003-0013-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
34 Berenguer M. Treatment of hepatitis C after liver transplantation. Clin Liver Dis 2005;9:579-600, vi. [PMID: 16207565 DOI: 10.1016/j.cld.2005.08.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
35 Takeuchi Y, Ikeda F, Osawa T, Araki Y, Takaguchi K, Morimoto Y, Hashimoto N, Sakaguchi K, Sakata T, Ando M, Makino Y, Matsumura S, Takayama H, Seki H, Nanba S, Moritou Y, Yasunaka T, Ohnishi H, Takaki A, Nouso K, Iwasaki Y, Yamamoto K. Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. World J Hepatol 2015; 7(19): 2220-2228 [PMID: 26380048 DOI: 10.4254/wjh.v7.i19.2220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
36 Shimomura S, Nishiguchi S. Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. Hepatol Res 2012;42:22-32. [PMID: 21951512 DOI: 10.1111/j.1872-034X.2011.00889.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
37 Nakamura J, Toyabe S, Aoyagi Y, Akazawa K. Economic impact of extended treatment with peginterferon α-2a and ribavirin for slow hepatitis C virologic responders. J Viral Hepat 2008;15:293-9. [DOI: 10.1111/j.1365-2893.2007.00943.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
38 Sanchez W, Talwalkar JA. Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am 2006;35:201-19. [PMID: 16530121 DOI: 10.1016/j.gtc.2005.12.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
39 Uyei J, Taddei TH, Kaplan DE, Chapko M, Stevens ER, Braithwaite RS. Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. PLoS One 2019;14:e0221614. [PMID: 31449554 DOI: 10.1371/journal.pone.0221614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
40 Cheng WS, Roberts SK, Mccaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, Yoshihara M, Dore GJ. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. Journal of Hepatology 2010;53:616-23. [DOI: 10.1016/j.jhep.2010.04.024] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
41 Di Marco V, Almasio P, Vaccaro A, Ferraro D, Parisi P, Cataldo MG, Di Stefano R, Craxì A. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. J Hepatol. 2000;33:456-462. [PMID: 11020002 DOI: 10.1016/S0168-8278(00)80282-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
42 Marrache F, Consigny Y, Ripault MP, Cazals-Hatem D, Martinot M, Boyer N, Degott C, Valla D, Marcellin P. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral Hepat. 2005;12:421-428. [PMID: 15985014 DOI: 10.1111/j.1365-2893.2005.00609.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
43 Wang H, Xu H, Qu L, Wang X, Wu R, Gao X, Jin Q, Niu J. Red blood cell distribution width and globulin, noninvasive indicators of fibrosis and inflammation in chronic hepatitis patients. Eur J Gastroenterol Hepatol. 2016;28:997-1002. [PMID: 27167453 DOI: 10.1097/meg.0000000000000662] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 4.2] [Reference Citation Analysis]
44 Foster GR, Suddle AR. Treatment of HCV infection with pegylated interferons. Curr hepatitis rep 2005;4:49-55. [DOI: 10.1007/s11901-005-0014-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
45 Everson GT. Management of cirrhosis due to chronic hepatitis C. J Hepatol. 2005;42 Suppl:S65-S74. [PMID: 15777574 DOI: 10.1016/j.jhep.2005.01.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
46 Persico M, Bruno S, Costantino A, Mazza M, Almasio PL. The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection. Int J Hepatol 2011;2011:314301. [PMID: 22164334 DOI: 10.4061/2011/314301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
47 Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44:20-29. [PMID: 14681338 DOI: 10.1177/0091270003258669] [Cited by in Crossref: 339] [Cited by in F6Publishing: 333] [Article Influence: 18.8] [Reference Citation Analysis]
48 Dutta U, Byth K, Kench J, Khan MH, Coverdale SA, Weltman M, Lin R, Liddle C, Farrell GC. Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study. Aust N Z J Med 1999;29:300-7. [PMID: 10868491 DOI: 10.1111/j.1445-5994.1999.tb00710.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
49 Mondelli MU, Silini E. Clinical significance of hepatitis C virus genotypes. Journal of Hepatology 1999;31:65-70. [DOI: 10.1016/s0168-8278(99)80377-8] [Cited by in Crossref: 67] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
50 Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL; HALT-C Trial Group. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010;138:136-46. [PMID: 19766643 DOI: 10.1053/j.gastro.2009.09.007] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
51 Khattak MN, Akhtar S, Mahmud S, Roshan TM. Factors influencing Hepatitis C virus sero-prevalence among blood donors in north west Pakistan. J Public Health Policy. 2008;29:207-225. [PMID: 18523475 DOI: 10.1057/jphp.2008.7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
52 Kang MJ, Jung EU, Park SW, Choi P, Kim JH, Park SJ, Park ET, Lee YJ, Lee SH, Seol SY. [Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection]. Korean J Hepatol 2008;14:318-30. [PMID: 18815455 DOI: 10.3350/kjhep.2008.14.3.318] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
53 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Fink SA, Jacobson IM. Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2011;8:285-95. [DOI: 10.1038/nrgastro.2011.57] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
55 Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003;10:285-93. [DOI: 10.1046/j.1365-2893.2003.00436.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 3.7] [Reference Citation Analysis]
56 Tamaki N, Kurosaki M, Tanaka K, Suzuki Y, Hoshioka Y, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Asahina Y, Izumi N. Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. J Viral Hepat 2013;20:72-6. [PMID: 23231087 DOI: 10.1111/j.1365-2893.2012.01635.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
57 Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231-264; quiz 214-217. [PMID: 16401486 DOI: 10.1053/j.gastro.2005.11.010] [Cited by in Crossref: 261] [Cited by in F6Publishing: 246] [Article Influence: 16.3] [Reference Citation Analysis]
58 Di Marco V, Almasio PL, Ferraro D, Calvaruso V, Alaimo G, Peralta S, Di Stefano R, Craxì A. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol. 2007;47:484-491. [PMID: 17692985 DOI: 10.1016/j.jhep.2007.04.020] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 5.2] [Reference Citation Analysis]
59 Tseng KC, Tseng CW, Hsieh YH, Chang CK, Lai NS, Hung TH, Chang TT. Effect of human leukocyte antigen class I and II alleles on hepatitis C viral load among chronic hepatitis C patients in Southern Taiwan. Hum Immunol 2013;74:978-82. [PMID: 23628398 DOI: 10.1016/j.humimm.2013.04.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
60 Im GY, Lubezky N, Facciuto ME, Schiano TD. Surgery in Patients with Portal Hypertension. Clinics in Liver Disease 2014;18:477-505. [DOI: 10.1016/j.cld.2014.01.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
61 Akimov S, Adeyemi OM. Peginterferon-α 2a in the treatment of chronic hepatitis C. Future Virology 2006;1:689-701. [DOI: 10.2217/17460794.1.6.689] [Reference Citation Analysis]
62 Craxì A, Cammà C. Prevention of hepatocellular carcinoma. Clin Liver Dis 2005;9:329-46, viii. [PMID: 15831277 DOI: 10.1016/j.cld.2004.12.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
63 Odhiambo R, Chhatwal J, Ferrante SA, El Khoury A, Elbasha E. Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. JHEOR 2013;1:62-82. [DOI: 10.36469/9854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
64 Crosbie OM, Alexander GJ. Liver transplantation for hepatitis C virus related cirrhosis. Best Practice & Research Clinical Gastroenterology 2000;14:307-25. [DOI: 10.1053/bega.1999.0078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
65 Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology. 2003;38:493-502. [PMID: 12883494 DOI: 10.1053/jhep.2003.50329] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 3.5] [Reference Citation Analysis]
66 El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36:S74-S83. [PMID: 12407579 DOI: 10.1053/jhep.2002.36807] [Cited by in Crossref: 34] [Cited by in F6Publishing: 135] [Article Influence: 1.7] [Reference Citation Analysis]
67 Berenguer M, Wright TL. TREATMENT STRATEGIES FOR RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION. Clinics in Liver Disease 1999;3:883-99. [DOI: 10.1016/s1089-3261(05)70245-2] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
68 Jafri S, Gordon SC. Care of the Cirrhotic Patient. Infectious Disease Clinics of North America 2012;26:979-94. [DOI: 10.1016/j.idc.2012.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
69 Kaplan DE, Reddy KR. Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. Clin Liver Dis 2003;7:683-714. [PMID: 14509534 DOI: 10.1016/s1089-3261(03)00060-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
70 Brown JL. Interferon therapy reduces the risk for hepatocellular carcinoma. Gut. 2000;47:610-611. [PMID: 11034573 DOI: 10.1136/gut.47.5.610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
71 Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Hisanaga Y. The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer 2000;88:58-65. [PMID: 10618606 DOI: 10.1002/(sici)1097-0142(20000101)88:1<58::aid-cncr9>3.0.co;2-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
72 Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol. 2001;35:666-678. [PMID: 11690716 DOI: 10.1016/s0168-8278(01)00179-9] [Cited by in Crossref: 222] [Cited by in F6Publishing: 45] [Article Influence: 11.1] [Reference Citation Analysis]
73 Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat. 2005;12:223-235. [PMID: 15850462 DOI: 10.1111/j.1365-2893.2005.00600.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.4] [Reference Citation Analysis]
74 Younossi ZM. Hepatitis C Infection: A Systemic Disease. Clin Liver Dis. 2017;21:449-453. [PMID: 28689584 DOI: 10.1016/j.cld.2017.03.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
75 Wong JB, Davis GL, Pauker SG. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med 2000;108:366-73. [PMID: 10759092 DOI: 10.1016/s0002-9343(00)00303-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
76 Kobayashi M, Ikeda K, Hosaka T, Sezaki H, Someya T, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, Miyakawa Y, Kumada H. Natural history of compensated cirrhosis in the Child-Pugh class a compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006;78:459-65. [DOI: 10.1002/jmv.20562] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
77 Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999;29:1311-1316. [PMID: 10094980 DOI: 10.1002/hep.510290424] [Cited by in Crossref: 186] [Cited by in F6Publishing: 186] [Article Influence: 8.1] [Reference Citation Analysis]
78 Craxì A, Cammà C. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons. Dig Liver Dis. 2010;42 Suppl 3:S287-S292. [PMID: 20547316 DOI: 10.1016/s1590-8658(10)60518-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
79 Yuen MF, Liu SH, Seto WK, Mak LY, Corman SL, Hsu DC, Lee MYK, Khan TK, Puenpatom A. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. Dig Dis Sci 2021;66:1315-26. [PMID: 32385703 DOI: 10.1007/s10620-020-06281-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
80 Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131-136. [PMID: 10861275 DOI: 10.1136/gut.47.1.131] [Cited by in Crossref: 257] [Cited by in F6Publishing: 231] [Article Influence: 11.7] [Reference Citation Analysis]
81 Toshikuni N, Izumi A, Nishino K, Inada N, Sakanoue R, Yamato R, Suehiro M, Kawanaka M, Yamada G. Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J Gastroenterol Hepatol. 2009;24:1276-1283. [PMID: 19486451 DOI: 10.1111/j.1440-1746.2009.05851.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
82 Kanda T. Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. Hepatol Int 2017;11:38-44. [PMID: 27282879 DOI: 10.1007/s12072-016-9749-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
83 Moreno-otero R. Therapeutic modalities in hepatitis C: challenges and development. J Viral Hepat 2005;12:10-9. [DOI: 10.1111/j.1365-2893.2005.00563.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
84 Diaz KE, Schiano TD. Evaluation and Management of Cirrhotic Patients Undergoing Elective Surgery. Curr Gastroenterol Rep 2019;21:32. [PMID: 31203525 DOI: 10.1007/s11894-019-0700-y] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
85 Macías-rodríguez MA, Rendón-unceta P, Martínez-sierra CM, Teyssiere-blas I, Díaz-garcía F, Martín-herrera L. Prognostic Usefulness of Ultrasonographic Signs of Portal Hypertension in Patients With Child–Pugh Stage A Liver Cirrhosis. American Journal of Gastroenterology 1999;94:3595-600. [DOI: 10.1111/j.1572-0241.1999.01548.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
86 Kimer N, Dahl EK, Gluud LL, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2012;2:e001313. [PMID: 23089208 DOI: 10.1136/bmjopen-2012-001313] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
87 Fabrizi F, Lunghi G, Poordad FF, Martin P. Genetic variability of hepatitis C virus in dialysis: the implications. Int J Artif Organs 2002;25:1034-48. [PMID: 12487391 DOI: 10.1177/039139880202501102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
88 Rumi MG, De Filippi F, La Vecchia C, Donato MF, Gallus S, Del Ninno E, Colombo M. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut. 2005;54:402-406. [PMID: 15710990 DOI: 10.1136/gut.2004.048009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
89 Lim EJ, Torresi J. Prevention of Hepatitis C Virus Infection and Liver Cancer. In: Chang MH, Jeang K, editors. Viruses and Human Cancer. Berlin: Springer Berlin Heidelberg; 2014. pp. 113-33. [DOI: 10.1007/978-3-642-38965-8_7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
90 Lee H, Cho Y, Kim HU, Choi EK, Hyun S, Kang D, Jeong SU, Kim HJ, Kim KS, Song B. Distribution of hepatitis C virus genotypes in Jeju Island. Korean J Hepatol 2008;14:28. [DOI: 10.3350/kjhep.2008.14.1.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
91 Bialek SR, Terrault NA. The Changing Epidemiology and Natural History of Hepatitis C Virus Infection. Clinics in Liver Disease 2006;10:697-715. [DOI: 10.1016/j.cld.2006.08.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
92 Abe T, Kuroda H, Fujiwara Y, Yoshida Y, Miyasaka A, Kamiyama N, Takikawa Y. Accuracy of 2D shear wave elastography in the diagnosis of liver fibrosis in patients with chronic hepatitis C. J Clin Ultrasound. 2018;46:319-327. [PMID: 29624693 DOI: 10.1002/jcu.22592] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
93 Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology. 2012;143:974-985.e14. [PMID: 22863764 DOI: 10.1053/j.gastro.2012.05.054] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 9.0] [Reference Citation Analysis]
94 Peters L, Rockstroh JK. Biomarkers of fibrosis and impaired liver function in chronic hepatitis C: how well do they predict clinical outcomes?: . Current Opinion in HIV and AIDS 2010;5:517-23. [DOI: 10.1097/coh.0b013e32833e3ee6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
95 Ray SC, Thomas DL. Hepatitis C. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 2157-85. [DOI: 10.1016/b978-0-443-06839-3.00154-5] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
96 Diamondstone LS, Aledort LM, Goedert JJ; MULTICENTRE HEMOPHILIA COHORT STUDY. Factors predictive of death among HIV-uninfected persons with haemophilia and other congenital coagulation disorders: ALL-CAUSE MORTALITY AMONG HIV-NEGATIVE HAEMOPHILIACS. Haemophilia 2002;8:660-7. [DOI: 10.1046/j.1365-2516.2002.00651.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
97 Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat. 2007;14:213-220. [PMID: 17305887 DOI: 10.1111/j.1365-2893.2006.00795.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
98 McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22:615-633. [PMID: 17444847 DOI: 10.1111/j.1440-1746.2007.04883.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 111] [Article Influence: 7.4] [Reference Citation Analysis]
99 Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, Rodriguez-Caravaca G, Bárcena R, Serra MA, Romero-Gómez M. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol. 2010;105:2164-1272; quiz 2173. [PMID: 20700116 DOI: 10.1038/ajg.2010.294] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
100 Willson RA, Fischer SH, Ochs HD. Long-term interferon alpha maintenance therapy for chronic hepatitis C infection in a patient with common variable immune deficiency. J Clin Gastroenterol. 1999;29:203-206. [PMID: 10478889 DOI: 10.1097/00004836-199909000-00023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
101 Jothimani D, Govil S, Rela M. Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. Hepatol Int 2016;10:749-61. [PMID: 27337961 DOI: 10.1007/s12072-016-9744-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
102 Fattovich G, Ribero ML, Pantalena M, Diodati G, Almasio P, Nevens F, Tremolada F, Degos F, Rai J, Solinas A, Mura D, Tocco A, Zagni I, Fabris F, Lomonaco L, Noventa F, Realdi G, Schalm SW, Tagger A; Eurohep Study Group on Viral Hepatitis. Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J Viral Hepat 2001;8:206-16. [PMID: 11380799 DOI: 10.1046/j.1365-2893.2001.00291.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
103 Toshikuni N, Arisawa T, Tsutsumi M. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol 2014; 20(11): 2876-2887 [PMID: 24659879 DOI: 10.3748/wjg.v20.i11.2876] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
104 Athanasakis K, Ferrante SA, Kyriopoulos II, Petrakis I, Hill M, Retsa MP, Kyriopoulos J. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis. Clin Ther 2015;37:1529-40. [PMID: 26031617 DOI: 10.1016/j.clinthera.2015.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
105 Ahmed A, Keeffe EB. Hepatitis C virus and liver transplantation. Clin Liver Dis. 2001;5:1073-1090. [PMID: 11685796 DOI: 10.1016/s1089-3261(05)70210-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
106 Castéra L, Bail BL, Roudot-thoraval F, Bernard P, Foucher J, Merrouche W, Couzigou P, de Lédinghen V. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: Comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. Journal of Hepatology 2009;50:59-68. [DOI: 10.1016/j.jhep.2008.08.018] [Cited by in Crossref: 259] [Cited by in F6Publishing: 223] [Article Influence: 19.9] [Reference Citation Analysis]
107 Yu M, Huang C, Dai C, Huang J, Chuang W. Long-Term Effects of Interferon-Based Therapy for Chronic Hepatitis C. Oncology 2007;72:16-23. [DOI: 10.1159/000111703] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
108 Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, Esteban-Mur R, Elbasha EH. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health 2013;16:973-86. [PMID: 24041347 DOI: 10.1016/j.jval.2013.07.006] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
109 Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131-136. [PMID: 10861275 DOI: 10.1136/gut.47.1.131.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Tseng KC, Ho YC, Hsieh YH, Lai NS, Wen ZH, Li C, Wu SF. Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. J Gastroenterol. 2012;47:823-833. [PMID: 22367277 DOI: 10.1007/s00535-012-0544-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
111 Kuo MJ, Chen HH, Chen CL, Fann JCY, Chen SLS, Chiu SYH, Lin YM, Liao CS, Chang HC, Lin YS, Yen AMF. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening. World J Gastroenterol 2016; 22(12): 3460-3470 [PMID: 27022228 DOI: 10.3748/wjg.v22.i12.3460] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
112 Braks RE, Ganne-Carrié N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, Trinchet JC. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13(42): 5648-5653 [PMID: 17948941 DOI: 10.3748/wjg.v13.i42.5648] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
113 Kubo S. Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy. Clin J Gastroenterol 2009;2:65-70. [DOI: 10.1007/s12328-009-0072-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
114 Cacoub P, Benhamou Y. Place des interférons dans le traitement des infections par les virusde l'hépatite B et de l'hépatite C. La Revue de Médecine Interne 2002;23:459S-74S. [DOI: 10.1016/s0248-8663(02)00660-4] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
115 Nakamura J, Kobayashi K, Toyabe S, Aoyagi Y, Akazawa K. The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. Eur J Gastroenterol Hepatol 2007;19:733-9. [PMID: 17700257 DOI: 10.1097/MEG.0b013e3282748f1f] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
116 Poynard T, Moussali J, Ratziu V, Regimbeau C, Opolon P. Effects of interferon therapy in “non responder” patients with chronic hepatitis C. Journal of Hepatology 1999;31:178-83. [DOI: 10.1016/s0168-8278(99)80397-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
117 Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005;48:71-75. [PMID: 15785093 DOI: 10.1159/000082098] [Cited by in Crossref: 40] [Cited by in F6Publishing: 50] [Article Influence: 2.4] [Reference Citation Analysis]
118 Toshikuni N, Arisawa T, Tsutsumi M. Nutrition and exercise in the management of liver cirrhosis. World J Gastroenterol 2014; 20(23): 7286-7297 [PMID: 24966599 DOI: 10.3748/wjg.v20.i23.7286] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
119 Macdonald GA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 1999;15:253-9. [DOI: 10.1097/00001574-199905000-00011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
120 Berenguer M, Wright TL. Hepatitis C and liver transplantation. Gut. 1999;45:159-163. [PMID: 10403720 DOI: 10.1136/gut.45.2.159] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 1.1] [Reference Citation Analysis]
121 Lee SS, Jeong S, Jang ES, Kim YS, Lee YJ, Jung EU, Kim IH, Bae SH, Lee HC, Kee M, Kang C. Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea: Outcomes of HCV-related cirrhosis. J Gastroenterol Hepatol 2015;30:1281-7. [DOI: 10.1111/jgh.12950] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
122 Kim WR. Models predicting the natural history of cirrhosis and need for liver transplantation: . Current Opinion in Organ Transplantation 2001;6:107-13. [DOI: 10.1097/00075200-200106000-00002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
123 Meyer-wyss B, Rich P, Egger H, Helbling B, Mullhaupt B, Rammert C, Gonvers J, Oneta C, Criblez D, Rossi L, Borovicka J, Meyenberger C, Arn M, Renner EL; Swiss Association for the Study of the Liver (SASL). Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 mug/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat 2006;13:457-65. [DOI: 10.1111/j.1365-2893.2005.00709.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
124 Mariano A, Scalia Tomba G, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis. 2009;41:689-699. [PMID: 19579149 DOI: 10.1080/00365540903095358] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
125 Delahooke TE. Hepatitis C: What is the nature of the problem? J Viral Hepat 2004;11 Suppl 1:5-11. [PMID: 15357857 DOI: 10.1111/j.1365-2893.2004.00569.x] [Reference Citation Analysis]
126 Westerhoff M, Ahn J. Chronic Hepatitis C and Direct Acting Antivirals. Surgical Pathology Clinics 2018;11:287-96. [DOI: 10.1016/j.path.2018.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
127 Zeuzem. Treatment of chronic hepatitis C virus infection in patients with cirrhosis. J Viral Hepat 2000;7:327-34. [DOI: 10.1046/j.1365-2893.2000.00229.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
128 Iwasaki Y, Takaguchi K, Ikeda H, Makino Y, Araki Y, Ando M, Kobashi H, Kobatake T, Tanaka R, Tomita M. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. Liver Int. 2004;24:603-610. [PMID: 15566511 DOI: 10.1111/j.1478-3231.2004.0956.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
129 Asselah T, Boudjema H, Francoz C, Sobesky R, Valla D, Belghiti J, Marcellin P, Durand F. Hépatite C et transplantation hépatique. Gastroentérologie Clinique et Biologique 2006;30:1281-95. [DOI: 10.1016/s0399-8320(06)73536-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
130 Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009;50:1142-1154. [PMID: 19395111 DOI: 10.1016/j.jhep.2009.01.019] [Cited by in Crossref: 148] [Cited by in F6Publishing: 147] [Article Influence: 11.4] [Reference Citation Analysis]
131 Harada N, Hiramatsu N, Oze T, Tatsumi T, Hayashi N, Takehara T. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma-A retrospective multicenter study: PegIFN/RBV Therapy After HCC Treatment. J Med Virol 2015;87:1199-206. [DOI: 10.1002/jmv.24173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
132 Forns X. [Treatment of chronic hepatitis C in cirrhosis of the liver]. Gastroenterol Hepatol 2002;25:356-9. [PMID: 11985814 DOI: 10.1016/s0210-5705(02)79038-9] [Reference Citation Analysis]
133 Syed E, Rahbin N, Weiland O, Carlsson T, Oksanen A, Birk M, Davidsdottir L, Hagen K, Hultcrantz R, Aleman S. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. Scand J Gastroenterol. 2008;43:1378-1386. [PMID: 18615358 DOI: 10.1080/00365520802245395] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
134 Nishiguchi S, Kubo S. Randomized Trial of Post-Operative Interferon Therapy After Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma and Long-Term Outcome. In: Omata M, Okita K, editors. Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma. Tokyo: Springer Japan; 2004. pp. 209-18. [DOI: 10.1007/978-4-431-53977-3_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
135 Yan M, Yang J, Sun Q, Liu C, Wang Y, Wang W. Hepatocellular carcinoma that arose from primary Sjögren’s syndrome. Annals of Hepatology 2013;12:824-9. [DOI: 10.1016/s1665-2681(19)31327-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
136 Aguilar C, Lucia JF, Simón MA. An emerging role for interferon in haemophiliacs with chronic hepatitis C? Haemophilia 2001;7:6-8. [PMID: 11136373 DOI: 10.1046/j.1365-2516.2001.00462.x] [Reference Citation Analysis]
137 Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis 2013;13:190. [PMID: 23621902 DOI: 10.1186/1471-2334-13-190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
138 Nguyen MH, Wright TL. Therapeutic advances in the management of hepatitis B and hepatitis C. Curr Opin Infect Dis. 2001;14:593-601. [PMID: 11964881 DOI: 10.1097/00001432-200110000-00014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
139 Deuffic-Burban S, Babany G, Lonjon-Domanec I, Deltenre P, Canva-Delcambre V, Dharancy S, Louvet A, Roudot-Thoraval F, Mathurin P. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology. 2009;50:1351-1359. [PMID: 19676130 DOI: 10.1002/hep.23159] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
140 Deuffic-Burban S, Deltenre P, Louvet A, Canva V, Dharancy S, Hollebecque A, Boitard J, Henrion J, Yazdanpanah Y, Mathurin P. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol. 2008;49:175-183. [PMID: 18538441 DOI: 10.1016/j.jhep.2008.04.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
141 Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Liddle C, Kench JG, Crewe E, Farrell GC. Effects of Interferon Treatment Response on Liver Complications of Chronic Hepatitis C: 9-year Follow-Up Study. Am J Gastroenterol 2004;99:636-44. [DOI: 10.1111/j.1572-0241.2004.04085.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
142 Bronowicki JP. [Antiviral treatments during cirrhosis]. Gastroenterol Clin Biol 2006;30:899-902. [PMID: 16885876 DOI: 10.1016/s0399-8320(06)73339-5] [Reference Citation Analysis]
143 Zavaglia C, Airoldi A, Pinzello G. Antiviral Therapy of HBV- and HCV-induced Liver Cirrhosis: . Journal of Clinical Gastroenterology 2000;30:234-41. [DOI: 10.1097/00004836-200004000-00006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
144 Tamaki N, Kurosaki M, Matsuda S, Nakata T, Muraoka M, Suzuki Y, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Matsunaga K, Taki K, Asahina Y, Izumi N. Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. Hepatol Res. 2014;44:720-727. [PMID: 23742243 DOI: 10.1111/hepr.12179] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
145 Lin SM, Tai DI, Chien RN, Sheen IS, Chu CM, Liaw YF. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat. 2004;11:349-357. [PMID: 15230858 DOI: 10.1111/j.1365-2893.2004.00512.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
146 Everson GT. Should we treat patients with chronic hepatitis C on the waiting list? J Hepatol. 2005;42:456-462. [PMID: 15763326 DOI: 10.1016/j.jhep.2005.01.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
147 Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R, Zhao X, Conry-Cantilena C, Kleiner DE, Liang TJ. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology. 2013;58:1548-1557. [PMID: 23703931 DOI: 10.1002/hep.26506] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 9.1] [Reference Citation Analysis]
148 Cabibbo G, Maida M, Genco C, Antonucci M, Cammà C. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol. 2012;39:374-383. [PMID: 22846856 DOI: 10.1053/j.seminoncol.2012.05.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
149 Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, Kamada T. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients. Int J Cancer 2000;87:741-9. [DOI: 10.1002/1097-0215(20000901)87:5<741::aid-ijc18>3.0.co;2-b] [Cited by in Crossref: 63] [Article Influence: 2.9] [Reference Citation Analysis]
150 Acharya C, Bajaj JS. Current Management of Hepatic Encephalopathy. Am J Gastroenterol. 2018;113:1600-1612. [PMID: 30002466 DOI: 10.1038/s41395-018-0179-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
151 Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006; 12(45): 7239-7249 [PMID: 17143937 DOI: 10.3748/wjg.v12.i45.7239] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
152 Delahooke TES, Hayes PC. Are Cirrhosis and its Complications Inevitable in Hepatitis C Virus Infection? Scott Med J 2000;45:35-7. [DOI: 10.1177/003693300004500201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
153 Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology. 2007;50:16-23. [PMID: 17164553 DOI: 10.1159/000096308] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
154 Nwankwo C, Corman SL, Elbasha EH. Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam. J Infect Public Health 2019;12:502-8. [PMID: 30711348 DOI: 10.1016/j.jiph.2019.01.054] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
155 Ganne-carrié N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, Dhumeaux D, Trinchet J, Beaugrand M. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006;44:1511-7. [DOI: 10.1002/hep.21420] [Cited by in Crossref: 349] [Cited by in F6Publishing: 343] [Article Influence: 21.8] [Reference Citation Analysis]
156 Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology. 2000;32:91-96. [PMID: 10869294 DOI: 10.1053/jhep.2000.8169] [Cited by in Crossref: 244] [Cited by in F6Publishing: 218] [Article Influence: 11.1] [Reference Citation Analysis]
157 Talwalkar JA, Kamath PS. Influence of Recent Advances in Medical Management on Clinical Outcomes of Cirrhosis. Mayo Clinic Proceedings 2005;80:1501-8. [DOI: 10.4065/80.11.1501] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
158 Lirussi F, Beccarello A, Bortolato L, Morselli-Labate AM, Crovatto M, Ceselli S, Santini G, Crepaldi G. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver. 1999;19:381-388. [PMID: 10533795 DOI: 10.1111/j.1478-3231.1999.tb00066.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
159 Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki WN, Wilkinson AH. GUIDELINES FOR THE REFERRAL AND MANAGEMENT OF PATIENTS ELIGIBLE FOR SOLID ORGAN TRANSPLANTATION: . Transplantation 2001;71:1189-204. [DOI: 10.1097/00007890-200105150-00001] [Cited by in Crossref: 141] [Cited by in F6Publishing: 94] [Article Influence: 6.7] [Reference Citation Analysis]
160 Helbling B, Jochum W, Stamenic I, Knöpfli M, Cerny A, Borovicka J, Gonvers JJ, Wilhelmi M, Dinges S, Müllhaupt B. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat. 2006;13:762-769. [PMID: 17052276 DOI: 10.1111/j.1365-2893.2006.00753.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
161 Biasiolo A, Martini A, Pontisso P. New biomarkers for clinical management of hepatitis C virus infected patients. World J Clin Infect Dis 2015; 5(4): 59-66 [DOI: 10.5495/wjcid.v5.i4.59] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
162 Poynard T, Opolon P. Hepatitis C: somber views of natural history and optimistic views of interferon treatment? Hepatology 1998;27:1443-4. [PMID: 9581705 DOI: 10.1002/hep.510270537] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
163 Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42:255-262. [PMID: 16025497 DOI: 10.1002/hep.20793] [Cited by in Crossref: 288] [Cited by in F6Publishing: 226] [Article Influence: 16.9] [Reference Citation Analysis]
164 Noureddin M, Ghany MG. Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment. Am J Gastroenterol 2010;105:2174-6. [PMID: 20927065 DOI: 10.1038/ajg.2010.288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
165 Cheinquer N, Cheinquer H, Wolff FH, Coelho-borges S. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis. The Brazilian Journal of Infectious Diseases 2010;14:457-61. [DOI: 10.1016/s1413-8670(10)70093-3] [Cited by in Crossref: 10] [Article Influence: 0.8] [Reference Citation Analysis]
166 Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: Coagulation and hepatic fibrogenesis. Clin Liver Dis. 2009;13:117-126. [PMID: 19150316 DOI: 10.1016/j.cld.2008.09.013] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
167 Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics. 2006;24:661-672. [PMID: 16802842 DOI: 10.2165/00019053-200624070-00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
168 Bardach A, Hernández-Vásquez A, Palacios A, Calderón M, Soto N, Balan D, Augustovski F. Epidemiología, consumo de recursos y costos del manejo médico de la Hepatitis C en Argentina, Colombia, Uruguay y Venezuela. Value Health Reg Issues 2019;20:180-90. [PMID: 31654963 DOI: 10.1016/j.vhri.2019.06.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-81. [PMID: 10428733 DOI: 10.7326/0003-4819-131-3-199908030-00003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
170 Kuroda H, Abe T, Kakisaka K, Fujiwara Y, Yoshida Y, Miyasaka A, Ishida K, Ishida H, Sugai T, Takikawa Y. Visualizing the hepatic vascular architecture using superb microvascular imaging in patients with hepatitis C virus: A novel technique. World J Gastroenterol 2016; 22(26): 6057-6064 [PMID: 27468197 DOI: 10.3748/wjg.v22.i26.6057] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
171 Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004;11:148-56. [DOI: 10.1046/j.1365-2893.2003.00481.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
172 Bartosch B, Thimme R, Blum HE, Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol. 2009;51:810-820. [PMID: 19545926 DOI: 10.1016/j.jhep.2009.05.008] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 7.3] [Reference Citation Analysis]
173 Hu KQ, Yang H, Lin YC, Lindsay KL, Redeker AG. Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. Int J Med Sci 2004;1:92-100. [PMID: 15912201 DOI: 10.7150/ijms.1.92] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
174 Tseng KC, Chou JL, Huang HB, Tseng CW, Wu SF, Chan MW. SOCS-1 promoter methylation and treatment response in chronic hepatitis C patients receiving pegylated-interferon/ribavirin. J Clin Immunol 2013;33:1110-6. [PMID: 23702664 DOI: 10.1007/s10875-013-9903-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
175 Corman S, Elbasha EH, Michalopoulos SN, Nwankwo C. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. Value in Health 2017;20:1110-20. [DOI: 10.1016/j.jval.2017.05.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
176 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 685] [Article Influence: 57.0] [Reference Citation Analysis]
177 Imazeki F, Yokosuka O, Fukai K, Kawai S, Kanda T, Kojima H, Saisho H. Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Liver Int. 2005;25:772-778. [PMID: 15998428 DOI: 10.1111/j.1478-3231.2005.01062.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
178 Lim EJ, Torresi J. Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results Cancer Res 2021;217:107-40. [PMID: 33200364 DOI: 10.1007/978-3-030-57362-1_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Goh PG, Kim MJ, Kim HJ, Eun HS, Kim ES, Kim YJ, Lee SY, Moon HS, Lee ES, Kim SH, Lee BS, Lee HY. Importance of Medication Adherence to Peginterferon-Ribavirin Combination Therapy in Patients with Chronic Hepatitis C. Korean J Gastroenterol 2011;57:294. [DOI: 10.4166/kjg.2011.57.5.294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
180 Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A, Borzio M, Solforosi L, Morabito A, Ideo G. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol. 2001;34:748-755. [PMID: 11434622 DOI: 10.1016/s0168-8278(01)00062-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
181 Esteban R. Can interferon prolong life? Hepatology 2003;38:292-4. [PMID: 12883472 DOI: 10.1053/jhep.2003.50337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
182 Elbasha E, Greaves W, Roth D, Nwankwo C. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States. J Viral Hepat 2017;24:268-79. [PMID: 27966249 DOI: 10.1111/jvh.12639] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
183 Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002;123:483-491. [PMID: 12145802 DOI: 10.1053/gast.2002.34785] [Cited by in Crossref: 168] [Cited by in F6Publishing: 151] [Article Influence: 8.4] [Reference Citation Analysis]
184 Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C, Machicao VI, Chaoru C, Nelson DR. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 2009;15:1063-1071. [PMID: 19718647 DOI: 10.1002/lt.21784] [Cited by in Crossref: 72] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
185 Regev A, Schiff ER. Viral hepatitis. Curr Opin Gastroenterol 1999;15:234-9. [PMID: 17023950 DOI: 10.1097/00001574-199905000-00008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
186 Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, Bourliere M, Boucher E, Miguet JP, Parlier D. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999;29:1870-1875. [PMID: 10347132 DOI: 10.1002/hep.510290616] [Cited by in Crossref: 157] [Cited by in F6Publishing: 142] [Article Influence: 6.8] [Reference Citation Analysis]
187 O’Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology. 2008;134:1764-1776. [PMID: 18471553 DOI: 10.1053/j.gastro.2008.02.028] [Cited by in Crossref: 120] [Cited by in F6Publishing: 87] [Article Influence: 8.6] [Reference Citation Analysis]
188 McCaughan GW. Asian perspectives on viral hepatitis: hepatitis C virus infection. J Gastroenterol Hepatol 2000;15 Suppl:G90-3. [PMID: 11101001 DOI: 10.1046/j.1440-1746.2000.02273.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
189 Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol. 1999;31 Suppl 1:17-24. [PMID: 10622555 DOI: 10.1016/s0168-8278(99)80369-9] [Cited by in Crossref: 219] [Cited by in F6Publishing: 91] [Article Influence: 10.0] [Reference Citation Analysis]
190 Omata M, Shiratori Y. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. J Gastroenterol Hepatol. 2000;15 Suppl:E134-E140. [PMID: 10921397 DOI: 10.1046/j.1440-1746.2000.02115.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
191 Izumi T, Sho T, Morikawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Umemura M, Shimazaki T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Kudo Y, Nishida M, Ono K, Baba M, Furuya K, Sakamoto N. Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. Hepatol Res. 2019;49:1207-1217. [PMID: 31219667 DOI: 10.1111/hepr.13391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
192 Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. [PMID: 15907199 DOI: 10.1186/1477-7819-3-27] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 5.0] [Reference Citation Analysis]
193 Farrell GC. Hepatocellular carcinoma after sustained response to interferon in non‐cirrhotic hepatitis C: Flaws in the cure, or a clue to the flaws? Journal of Gastroenterology and Hepatology 2001;14:833-7. [DOI: 10.1046/j.1440-1746.1999.01977.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
194 Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002;89:418-422. [PMID: 11952580 DOI: 10.1046/j.0007-1323.2001.02054.x] [Cited by in Crossref: 118] [Cited by in F6Publishing: 118] [Article Influence: 5.9] [Reference Citation Analysis]
195 Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Kench J, Kaba S, Crewe E. Which patients with hepatitis C develop liver complications? Hepatology. 2000;31:513-520. [PMID: 10655279 DOI: 10.1002/hep.510310236] [Cited by in Crossref: 110] [Cited by in F6Publishing: 115] [Article Influence: 5.0] [Reference Citation Analysis]
196 Hu SX, Kyulo NL, Xia VW, Hillebrand DJ, Hu KQ. Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients. J Clin Gastroenterol. 2009;43:758-764. [PMID: 19238091 DOI: 10.1097/mcg.0b013e31818be17c] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
197 Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744-749. [PMID: 15082595 DOI: 10.1136/gut.2003.020263] [Cited by in Crossref: 315] [Cited by in F6Publishing: 279] [Article Influence: 17.5] [Reference Citation Analysis]
198 Shiell A, Law MG. The cost of hepatitis C and the cost-effectiveness of its prevention. Health Policy. 2001;58:121-131. [PMID: 11551662 DOI: 10.1016/s0168-8510(01)00159-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
199 Everson GT. Treatment of hepatitis C in patients who have decompensated cirrhosis. Clin Liver Dis. 2005;9:473-486, viii. [PMID: 16023978 DOI: 10.1016/j.cld.2005.05.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
200 Yao F, Terrault N. Hepatitis C and hepatocellular carcinoma. Curr Treat Options in Oncol 2001;2:473-83. [DOI: 10.1007/s11864-001-0069-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
201 Yatsuhashi H, Yano M. Natural history of chronic hepatitis C. J Gastroenterol Hepatol 2000;15:E111-6. [DOI: 10.1046/j.1440-1746.2000.02122.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 0.9] [Reference Citation Analysis]
202 Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther. 2001;15:689-698. [PMID: 11328263 DOI: 10.1046/j.1365-2036.2001.00979.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 4.5] [Reference Citation Analysis]
203 Shiratori Y, Omata M. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? J Gastroenterol Hepatol. 2000;15 Suppl:E141-E151. [PMID: 10921398 DOI: 10.1046/j.1440-1746.2000.02116.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
204 D’amico G, Perricone G. Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter? Curr Hepatology Rep 2019;18:144-56. [DOI: 10.1007/s11901-019-00473-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
205 Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, Kanzler S. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 2009; 15(5): 578-582 [PMID: 19195059 DOI: 10.3748/wjg.15.578] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
206 Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007; 13(39): 5188-5195 [PMID: 17876889 DOI: 10.3748/wjg.v13.i39.5188] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
207 Nakano I, Fukuda Y, Katano Y, Toyoda H, Hayashi K, Kumada T, Nakano S. Japan-specific subtype of hepatitis C virus genotype 1b, J subtype, has relatively low pathogenicity. J Med Virol 2001;65:45-51. [DOI: 10.1002/jmv.1099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
208 O'Leary JG, Davis GL. Hepatitis C virus replication and potential targets for direct-acting agents. Therap Adv Gastroenterol 2010;3:43-53. [PMID: 21180589 DOI: 10.1177/1756283X09353353] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
209 Bonkovsky HL, Mehta S. Hepatitis C: A review and update. Disease-a-Month 2001;47:610-47. [DOI: 10.1016/s0011-5029(01)90007-0] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
210 Gomez EV, Rodriguez YS, Bertot LC, Gonzalez AT, Perez YM, Soler EA, Garcia AY, Blanco LP. The natural history of compensated HCV-related cirrhosis: a prospective long-term study. J Hepatol. 2013;58:434-444. [PMID: 23111008 DOI: 10.1016/j.jhep.2012.10.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
211 Franco J, Saeian K. Role of Antiviral Therapy in the Prevention of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2002;13:S191-6. [DOI: 10.1016/s1051-0443(07)61786-2] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
212 Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001;34:593-602. [PMID: 11394661 DOI: 10.1016/s0168-8278(01)00005-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 65] [Article Influence: 13.0] [Reference Citation Analysis]
213 Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971-975. [PMID: 10051505 DOI: 10.1002/hep.510290312] [Cited by in Crossref: 315] [Cited by in F6Publishing: 287] [Article Influence: 13.7] [Reference Citation Analysis]
214 Hu K, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001;8:1-18. [DOI: 10.1046/j.1365-2893.2001.00253.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 2.5] [Reference Citation Analysis]
215 Zhao C, Nguyen MH. Hepatocellular Carcinoma Screening and Surveillance: Practice Guidelines and Real-Life Practice. J Clin Gastroenterol. 2016;50:120-133. [PMID: 26583266 DOI: 10.1097/mcg.0000000000000446] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
216 Bain VG. Effect of HCV viral dynamics on treatment design: lessons learned from HIV. Am J Gastroenterol 2001;96:2818-28. [PMID: 11693314 DOI: 10.1111/j.1572-0241.2001.04234.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
217 Nguyen HA, Ho SB. Natural history of chronic hepatitis C: Identifying a window of opportunity for intervention. Disease-a-Month 2001;47:593-609. [DOI: 10.1016/s0011-5029(01)90006-9] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
218 Deuffic-burban S, Mathurin P, Valleron A. Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. Stat Methods Med Res 2009;18:233-52. [DOI: 10.1177/0962280208094697] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
219 Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, Sung JJ. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol. 2005;100:616-623. [PMID: 15743360 DOI: 10.1111/j.1572-0241.2005.41289.x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 135] [Article Influence: 8.2] [Reference Citation Analysis]
220 Hollinger FB. Factors contributing to the evolution and outcome of cirrhosis in hepatitis C. Clin Liver Dis 1999;3:741-55, viii. [PMID: 11291248 DOI: 10.1016/s1089-3261(05)70236-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
221 Rosen HR, Gretch DR. Hepatitis C virus: current understanding and prospects for future therapies. Mol Med Today 1999;5:393-9. [PMID: 10462751 DOI: 10.1016/s1357-4310(99)01523-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
222 Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-78. [PMID: 11690716 DOI: 10.1016/s0168-8278(01)00179-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
223 Bang CS, Song IH. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol 2017;17:46. [PMID: 28376711 DOI: 10.1186/s12876-017-0606-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
224 El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36:S74-S83. [PMID: 12407579 DOI: 10.1002/hep.1840360710] [Cited by in Crossref: 195] [Cited by in F6Publishing: 127] [Article Influence: 9.8] [Reference Citation Analysis]
225 Rust C, Gores GJ. Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies. Clin Liver Dis. 2001;5:161-173. [PMID: 11218913 DOI: 10.1016/s1089-3261(05)70159-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
226 Chuang E, Del Vecchio A, Smolinski S, Song XY, Sarisky RT. Biomedicines to reduce inflammation but not viral load in chronic HCV--what’s the sense? Trends Biotechnol. 2004;22:517-523. [PMID: 15450745 DOI: 10.1016/j.tibtech.2004.08.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
227 Stribling R, Sussman N, Vierling JM. Treatment of hepatitis C infection. Gastroenterol Clin North Am. 2006;35:463-486. [PMID: 16880075 DOI: 10.1016/j.gtc.2006.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
228 Tokunaga M, Uto H, Oda K, Tokunaga M, Mawatari S, Kumagai K, Haraguchi K, Oketani M, Ido A, Ohnou N, Utsunomiya A, Tsubouchi H. Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Gastroenterol 2014;49:1567-77. [DOI: 10.1007/s00535-013-0928-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
229 Deuffic-Burban S, Mathurin P, Rosa I, Bouvier AM, Cannesson A, Mourad A, Canva V, Louvet A, Deltenre P, Boleslawski E. Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach. Dig Liver Dis. 2014;46:157-163. [PMID: 24119483 DOI: 10.1016/j.dld.2013.08.137] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
230 Shad JA, McHutchison JG. Current and future therapies of hepatitis C. Clin Liver Dis 2001;5:335-59. [PMID: 11385967 DOI: 10.1016/s1089-3261(05)70169-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
231 Chinnaratha MA, Jeffrey GP, Macquillan G, Rossi E, de Boer BW, Speers DJ, Adams LA. Prediction of morbidity and mortality in patients with chronic hepatitis C by non-invasive liver fibrosis models. Liver Int 2014;34:720-7. [DOI: 10.1111/liv.12306] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
232 Bonino F, Oliveri F, Colombatto P, Coco B, Mura D, Realdi G, Brunetto M. Treatment of patients with chronic hepatitis C and cirrhosis. Journal of Hepatology 1999;31:197-200. [DOI: 10.1016/s0168-8278(99)80401-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
233 Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol. 2005;40:688-696. [PMID: 16036529 DOI: 10.1080/00365520510015467] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
234 Molina Pérez E, Fernández Castroagudín J, Domínguez Muñoz E. [Current indications for triple therapy in hepatitis C virus infection]. Gastroenterol Hepatol 2012;35:266-77. [PMID: 22410706 DOI: 10.1016/j.gastrohep.2012.01.003] [Reference Citation Analysis]
235 El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576. [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061] [Cited by in Crossref: 3516] [Cited by in F6Publishing: 3469] [Article Influence: 234.4] [Reference Citation Analysis]
236 Okuno M, Kojima S, Moriwaki H. Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. J Gastroenterol Hepatol. 2001;16:1329-1335. [PMID: 11851828 DOI: 10.1046/j.1440-1746.2001.02634.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
237 Tsai PC, Huang CI, Yeh ML, Huang CF, Hsieh MH, Yang JF, Hsu PY, Liang PC, Lin YH, Jang TY, Hsieh MY, Dai CY, Lin ZY, Chen SC, Huang JF, Yu ML, Chuang WL, Chang WY. Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan. BMJ Open 2021;11:e042861. [PMID: 33722868 DOI: 10.1136/bmjopen-2020-042861] [Reference Citation Analysis]
238 Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci. 2011;56:1853-1861. [PMID: 21374066 DOI: 10.1007/s10620-011-1621-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
239 Fattovich G, Schalm SW. 12 Hepatitis C and cirrhosis. Hepatitis C. Elsevier; 2000. pp. 241-63. [DOI: 10.1016/s1874-5326(00)80016-2] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
240 Shakado S, Sakisaka S, Chayama K, Okanoue T, Toyoda J, Izumi N, Matsumoto A, Takehara T, Ido A, Hiasa Y, Yoshioka K, Nomura H, Ueno Y, Seike M, Kumada H. Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. World J Hepatol 2015; 7(27): 2757-2764 [PMID: 26644819 DOI: 10.4254/wjh.v7.i27.2757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
241 Chen HM, Wan H, Yu M, Tian XL, Wei L, Xu XY. Relationship between HCV RNA quantities and HCV genotypes and the outcome of patients with posttransfusion hepatitis C virus infection. Shijie Huaren Xiaohua Zazhi 2004; 12(6): 1299-1302 [DOI: 10.11569/wcjd.v12.i6.1299] [Reference Citation Analysis]
242 O'Leary JG, Yachimski PS, Friedman LS. Surgery in the patient with liver disease. Clin Liver Dis. 2009;13:211-231. [PMID: 19442915 DOI: 10.1016/j.cld.2009.02.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
243 Tsai PC, Liu TW, Tsai YS, Ko YM, Chen KY, Lin CC, Huang CI, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML. Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database. Medicine (Baltimore) 2017;96:e6984. [PMID: 28562549 DOI: 10.1097/MD.0000000000006984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
244 Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54:396-405. [PMID: 21520194 DOI: 10.1002/hep.24370.24370] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
245 Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol. 2001;79:515-536. [PMID: 11903612 DOI: 10.1046/j.1440-1711.2001.01036.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 3.1] [Reference Citation Analysis]
246 Heathcote EJ. Treatment Considerations in Patients With Hepatitis C and Cirrhosis: . Journal of Clinical Gastroenterology 2003;37:395-8. [DOI: 10.1097/00004836-200311000-00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
247 Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res. 2015;45:152-161. [PMID: 25052449 DOI: 10.1111/hepr.12393] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.8] [Reference Citation Analysis]
248 Younossi ZM, Birerdinc A, Henry L. Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. Journal of Hepatology 2016;65:S109-19. [DOI: 10.1016/j.jhep.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
249 Obika M, Shinji T, Fujioka S, Terada R, Ryuko H, Lwin AA, Shiraha H, Koide N. Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study. Intervirology. 2008;51:59-68. [PMID: 18349544 DOI: 10.1159/000121363] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
250 Fartoux L, Degos F, Trépo C, Goria O, Calès P, Tran A, Buffet C, Poynard T, Capron D, Raabe JJ. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol. 2007;5:502-507. [PMID: 17261383 DOI: 10.1016/j.cgh.2006.10.016] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
251 . Chapter 1: Prevention: Chapter 1: Prevention. Hepatology Research 2010;40:10-5. [DOI: 10.1111/j.1872-034x.2010.00654.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
252 Gramenzi A, Andreone P, Fiorino S, Cammà C, Giunta M, Magalotti D, Cursaro C, Calabrese C, Arienti V, Rossi C. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut. 2001;48:843-848. [PMID: 11358906 DOI: 10.1136/gut.48.6.843] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 3.0] [Reference Citation Analysis]
253 Herrine SK, Navarro VJ. Antiviral therapy of HCV in the cirrhotic and transplant candidate. Int J Med Sci 2006;3:75-8. [PMID: 16614747 DOI: 10.7150/ijms.3.75] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
254 Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. Aliment Pharmacol Ther 2017;45:455-67. [PMID: 27910116 DOI: 10.1111/apt.13882] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
255 Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, Komatsu T, Taguri M, Tanaka K. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 2019;8:1054-65. [PMID: 30791221 DOI: 10.1002/cam4.1998] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
256 Nahon P, Ganne-carrié N, Degos F, Nahon K, Paries J, Grando V, Chaffaut C, Njapoum C, Christidis C, Trinchet J, Chevret S, Beaugrand M. Serum albumin and platelet count but not portal pressure are predictive of death in patients with Child-Pugh A hepatitis C virus-related cirrhosis. Gastroentérologie Clinique et Biologique 2005;29:347-52. [DOI: 10.1016/s0399-8320(05)80779-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
257 Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, Beinhardt S, Kundi M, Ferenci P, Gangl A, Trauner M. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 2011;9:602-608.e1. [PMID: 21397726 DOI: 10.1016/j.cgh.2011.03.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
258 Acharya C, Bajaj JS. Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46:155-169. [PMID: 28164848 DOI: 10.1016/j.gtc.2016.09.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
259 Vandenbulcke H, Moreno C, Colle I, Knebel JF, Francque S, Sersté T, George C, de Galocsy C, Laleman W, Delwaide J, Orlent H, Lasser L, Trépo E, Van Vlierberghe H, Michielsen P, van Gossum M, de Vos M, Marot A, Doerig C, Henrion J, Deltenre P. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. J Hepatol 2016;65:543-51. [PMID: 27180899 DOI: 10.1016/j.jhep.2016.04.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
260 Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 2002;17:423-30. [PMID: 11982723 DOI: 10.1046/j.1440-1746.2002.02730.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 3.6] [Reference Citation Analysis]
261 Matser A, Urbanus A, Geskus R, Kretzschmar M, Xiridou M, Buster M, Coutinho R, Prins M. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 2012;107:614-23. [PMID: 21919987 DOI: 10.1111/j.1360-0443.2011.03654.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
262 Donlin MJ, Lomonosova E, Kiss A, Cheng X, Cao F, Curto TM, Di Bisceglie A, Tavis JE. HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma. PLoS One 2014;9:e103748. [PMID: 25079603 DOI: 10.1371/journal.pone.0103748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
263 Kalambokis G, Manousou P, Samonakis D, Grillo F, Dhillon AP, Patch D, O’Beirne J, Rolles K, Burroughs AK. Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int. 2009;22:172-181. [PMID: 18786149 DOI: 10.1111/j.1432-2277.2008.00744.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
264 Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E; European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886-2895. [PMID: 12425564 DOI: 10.1111/j.1572-0241.2002.07057.x] [Cited by in Crossref: 219] [Cited by in F6Publishing: 219] [Article Influence: 11.0] [Reference Citation Analysis]
265 Obara N, Ueno Y, Fukushima K, Nakagome Y, Kakazu E, Kimura O, Wakui Y, Kido O, Ninomiya M, Kogure T. Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J Gastroenterol. 2008;43:720-728. [PMID: 18807134 DOI: 10.1007/s00535-008-2225-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
266 Kan T, Hashimoto S, Kawabe N, Nakano T, Nakaoka K, Yoshioka K. Increase in Albumin by Daclatasvir/asunaprevir Therapy is Correlated with Decrease in Aspartate Transaminase. J Transl Int Med 2017;5:148-54. [PMID: 29085787 DOI: 10.1515/jtim-2017-0028] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
267 Nguyen HA, Ho SB. Natural history of chronic hepatitis C: Identifying a window of opportunity for intervention. Journal of Laboratory and Clinical Medicine 2001;137:146-54. [DOI: 10.1067/mlc.2001.113038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
268 Poordad F, Castro RE, Asatryan A, Aguilar H, Cacoub P, Dieterich D, Marinho RT, Carvalho A, Siddique A, Hu YB, Charafeddine M, Bondin M, Khan N, Cohen DE, Felizarta F. Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials. J Viral Hepat 2020;27:497-504. [PMID: 31954087 DOI: 10.1111/jvh.13261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
269 Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol. 1999;31 Suppl 1:237-243. [PMID: 10622595 DOI: 10.1016/s0168-8278(99)80409-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
270 Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology. 2004;127:S62-S71. [PMID: 15508105 DOI: 10.1053/j.gastro.2004.09.017] [Cited by in Crossref: 156] [Cited by in F6Publishing: 134] [Article Influence: 8.7] [Reference Citation Analysis]
271 Calvaruso V, Craxì A. Fibrosis in chronic viral hepatitis. Best Pract Res Clin Gastroenterol. 2011;25:219-230. [PMID: 21497740 DOI: 10.1016/j.bpg.2011.02.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
272 Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Hepatology 2014;59:1471-81. [PMID: 24677195 DOI: 10.1002/hep.26944] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
273 Höroldt B, Haydon G, O’Donnell K, Dudley T, Nightingale P, Mutimer D. Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. Liver Int. 2006;26:650-659. [PMID: 16842320 DOI: 10.1111/j.1478-3231.2006.01272.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
274 Bonkovsky HL, Mehta S. Hepatitis C: A review and update. Journal of the American Academy of Dermatology 2001;44:159-82. [DOI: 10.1067/mjd.2001.109311] [Cited by in Crossref: 70] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]